Assembly Biosciences, Inc. ASMB

Competitive advantage analysis · healthcare

Corporate Default
Overall moat score
60/100
Moderate

Ranked against 712 peers in Biotechnology

About Assembly Biosciences, Inc.

Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases worldwide. Its pipeline includes long-acting helicase-primase inhibitors candidates, including ABI-5336 and ABI-1179, which are in Phase 1a/1b clinical studies for recurrent genital herpes; ABI-4334, a capsid assembly modulator designed to disrupt the replication cycle of hepatitis B virus that is in Phase 1b clinical study; … Full ASMB analysis →

Key strengths

  • Cost Leadership Position Operating margin at 82.5th percentile with strong OpEx control demonstrates cost leadership.
  • Scale Supporting Profitability Profitability at scale is strong (score 0.91), demonstrating competitive advantages.

Key risks

  • Elevated Debt Risk Debt serviceability is weak (score 0.26), raising refinancing risk.
  • Revenue Volatility Signals Weak Stickiness Revenue volatility is high (stability score 0.34), suggesting weak customer stickiness.

The dashed ring is the peer median. Defense scores are percentile ranks against peers, so 50 is roughly the typical company in this group.

Upgrade to unlock the signals and evidence behind each defense.

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power

Developing
47
Premium

Signals, strengths and risks for Pricing Power

Premium

Signals, strengths and risks for Cost Advantage

Premium

Signals, strengths and risks for Customer Stickiness

Premium

Signals, strengths and risks for Capital Efficiency

Premium

Signals, strengths and risks for Resilience

Premium

Signals, strengths and risks for Scale & Market Position

Where ASMB ranks in Biotechnology

Assembly Biosciences, Inc. ranks #106 of 713 scored companies in Biotechnology by moat score — the top 15%. The widest moat in the group is Royalty Pharma plc (RPRX) at 85/100.

# Company Moat score Rating
102 Tourmaline Bio, Inc. TRML 60/100 Moderate
103 Edgewise Therapeutics, Inc. EWTX 60/100 Moderate
104 Mirum Pharmaceuticals, Inc. MIRM 60/100 Moderate
105 Enanta Pharmaceuticals, Inc. ENTA 60/100 Moderate
106 Assembly Biosciences, Inc. ASMB 60/100 Moderate
107 CytomX Therapeutics, Inc. CTMX 60/100 Moderate
108 Mesoblast Limited MESO 60/100 Moderate
109 Travere Therapeutics, Inc. TVTX 60/100 Moderate
110 AEON Biopharma, Inc. AEON 60/100 Moderate

See every Biotech / Pre-Revenue company ranked by moat score →

How ASMB scores on the Corporate Default defenses

Pricing Power

Score 47 · 20% of the moat score

Pricing power is the ability to raise prices without losing volume.

Cost Advantage

Score 87 · 15% of the moat score

A cost advantage means delivering the same product for structurally less — better purchasing, denser distribution, a more automated process.

Customer Stickiness

Score 59 · 15% of the moat score

Stickiness is what makes revenue repeat without being re-won every year.

Capital Efficiency

Score 46 · 18% of the moat score

Capital efficiency asks what the company earns on the money tied up in the business.

Resilience

Score 45 · 17% of the moat score

Resilience is the capacity to get through a bad year on its own terms — enough liquidity, enough interest cover, and enough cash generation to avoid a rescue financing or a forced sale.

Scale & Market Position

Score 84 · 15% of the moat score

Scale matters only when it converts into economics.

How each Corporate Default defense is measured, in full →

Understanding ASMB's moat

What is Assembly Biosciences, Inc.'s moat score?

Assembly Biosciences, Inc. (ASMB) scores 60 out of 100 on the StatsAlpha Moat Map, which rates its competitive advantage as moderate. It ranks #106 of 713 scored companies in Biotechnology, the top 15%. The score is a weighted composite of 6 competitive defenses, each measured against industry peers of 712 companies in Biotechnology. Its strongest defense is Cost Advantage (87/100) and its weakest is Resilience (45/100).

How does Assembly Biosciences, Inc. compare with other Biotechnology companies?

Assembly Biosciences, Inc. ranks #106 of 713 scored companies in Biotechnology by moat score. The widest moat in Biotechnology is Royalty Pharma plc (RPRX) at 85/100. The companies ranked closest are Enanta Pharmaceuticals, Inc. (ENTA) at 60 just above it and CytomX Therapeutics, Inc. (CTMX) at 60 just below it.

How is the moat score calculated?

Each company is scored with an industry-specific template — Corporate Default in this case, chosen because the defenses that matter to a bank are not the ones that matter to a software company. Every defense combines several financial signals, and each signal is measured as a percentile against a peer group of 712 companies in Biotechnology. The defenses are then weighted to produce the overall score out of 100.

Why is Assembly Biosciences, Inc. scored with the Corporate Default template?

Most public companies sell a product or a service at a margin, so the moat question is whether that margin survives contact with competitors. The Corporate template scores the six defenses that show up in a general operating company's financial signature: whether it can hold price, produce more cheaply than rivals, keep its customers, earn a return above its cost of capital, withstand a downturn, and turn size into economics.

Which competitive defenses are measured for Assembly Biosciences, Inc.?

The Corporate Default template measures 6 defenses, and ASMB scores: Pricing Power (47), Cost Advantage (87), Customer Stickiness (59), Capital Efficiency (46), Resilience (45), Scale & Market Position (84). Each is scored independently as a percentile against peers, so a company can be strong on one and weak on another — the overall score reflects how those defenses are weighted for this industry.

Send Feedback
Please select a category.
0/1000